
About two weeks ago, news media began reporting that millions of Australians had become eligible for access to new antiviral drugs – COVID-19 treatments that are apparently effective in preventing severe disease.
The point of these drugs – nirmatrelvir–ritonavir (Paxlovid) and molnupiravir (Lagevrio) – is to catch a COVID-19 infection early and prevent it from becoming a killer case.